title: Clinicopathological features of prostate ductal carcinoma: matching analysis and comparison with prostate acinar carcinoma.
abstract: We evaluated the clinicopathological features and prognosis of 29 cases of prostate ductal carcinoma was considered to be an aggressive subtype of prostate acinar carcinoma. We selected 29 cases who were diagnosed prostate ductal carcinoma and had a radical prostatectomy (RP). The acinar group (n = 116) was selected among 3,980 patients who underwent a prostatectomy. The acinar group was matched to the ductal group for prostate specific antigen (PSA), clinical stage, Gleason score, and age. The mean (range) of the follow-up periods for the ductal and acinar group was 23.8 ± 20.6 and 58 ± 10.5 months, respectively. The mean age of the prostate ductal and acinar carcinoma patients was 67.3 and 67.0 yr and the mean PSA level was 14.7 and 16.2 ng/mL, respectively. No statistical differences were evident between groups in terms of the final pathologic stage or positive resection margin rate other than the postoperative Gleason score. A greater proportion of the ductal group demonstrated a postoperative Gleason score ≥ 8 in comparison with the acinar group (P = 0.024). Additionally, we observed significant prognostic difference in our patient series in biochemical recurrence. The ductal group showed a poorer prognosis than the acinar group (P = 0.016). There were no differences significantly in terms of final pathology and rate of positive resection margin, but a greater proportion of the ductal group demonstrated a Gleason score ≥ 8 than the acinar group after matching for PSA, Gleason score in biopsy and clinical stage. The ductal group also showed a poorer prognosis.
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Aram
authors.identifier: 0000-0001-9945-4683
authors.initials: A
authors.lastname: Kim
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Taekmin
authors.initials: T
authors.lastname: Kwon
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Dalsan
authors.initials: D
authors.lastname: You
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: In Gab
authors.initials: IG
authors.lastname: Jeong
authors.affiliation: Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Heounjeong
authors.initials: H
authors.lastname: Go
authors.affiliation: Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Yong Mee
authors.initials: YM
authors.lastname: Cho
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Jun Hyuk
authors.initials: JH
authors.lastname: Hong
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Hanjong
authors.initials: H
authors.lastname: Ahn
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Choung-Soo
authors.identifier: 0000-0002-7464-3207
authors.initials: CS
authors.lastname: Kim
mesh_terms: D000368:Aged; D018267:Carcinoma, Acinar Cell / Q000473:pathology*; D044584:Carcinoma, Ductal / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology*; D018426:SEER Program
chemical_list: D017430:Prostate-Specific Antigen
keywords: Disease Progression; Prostate Neoplasms; Prostatectomy; Recurrence
references.citation: Am J Surg Pathol. 1999 Dec;23(12):1471-9
references.pmid: 10584700
references.citation: Cancer. 1973 Aug;32(2):402-9
references.pmid: 4124700
references.citation: Urology. 1976 Aug;8(2):169-73
references.pmid: 960351
references.citation: J Urol. 1979 Mar;121(3):303-5
references.pmid: 219263
references.citation: Cancer. 1986 Jan 1;57(1):111-9
references.pmid: 2416422
references.citation: Am J Surg Pathol. 1985 Aug;9(8):595-609
references.pmid: 4091189
references.citation: Semin Diagn Pathol. 1988 Aug;5(3):301-11
references.pmid: 2845546
references.citation: Mod Pathol. 2006 Dec;19(12):1528-35
references.pmid: 16980940
references.citation: Arch Pathol Lab Med. 2007 Jul;131(7):1103-9
references.pmid: 17616999
references.citation: Urol Oncol. 2008 Jul-Aug;26(4):368-71
references.pmid: 18367098
references.citation: Cancer. 2009 Jul 1;115(13):2872-80
references.pmid: 19402048
references.citation: Mod Pathol. 2009 Oct;22(10):1273-9
references.pmid: 19633648
references.citation: J Urol. 2010 Feb;183(2):433-40
references.pmid: 20006878
references.citation: Pathology. 2010 Jun;42(4):319-24
references.pmid: 20438402
references.citation: J Urol. 2010 Oct;184(4):1328-33
references.pmid: 20723921
references.citation: Am J Surg Pathol. 2011 Apr;35(4):615-9
references.pmid: 21383610
references.citation: Histopathology. 2012 Jan;60(1):59-74
references.pmid: 22212078
references.citation: BJU Int. 2012 Mar;109(6):831-4
references.pmid: 21883856
references.citation: Virchows Arch. 2013 Apr;462(4):429-36
references.pmid: 23443941
references.citation: Histopathology. 2013 Jul;63(1):57-63
references.pmid: 23701402